Telix Pharmaceuticals (Innovations) Pty Limited
Quick facts
Phase 3 pipeline
- 177Lu-TLX591 · Oncology
177Lu-TLX591 is a lutetium-177 labeled radioligand that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to deliver targeted radiotherapy.
Phase 2 pipeline
- 177Lu-DOTA-TLX591 · Oncology
177Lu-DOTA-TLX591 is a radiolabeled peptide that targets the prostate-specific membrane antigen (PSMA) for targeted alpha-particle therapy.
Phase 1 pipeline
- 131I-IPA · Oncology
Iodine-131 labelled peptide for targeted radionuclide therapy - 153Sm-DOTMP · Oncology
A radioligand targeting somatostatin receptors - 64Cu-DOTA-TLX592 · Oncology
Somatostatin receptor targeting
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: